Breadcrumb
- Home
- Search a publication
- Opioid substitution treatment in France: 2023 repo...
The aim of this document is to present updated data on opioid substitution treatment in France. It is based on the latest available data, the year of which may vary from 2019 to 2022 depending on the source and the treatment period.
The first part of the briefing paper describes the sociodemographic breakdown of people receiving payment for opioid substitution medications (OSM) in primary care in 2020, as well as their treatment methods.
These data come from the simplified generalist sample of recipients (EGBS) of the French National Health Insurance Fund. They are supplemented by the data on prescriptions and supply of OSMs in CSAPA specialised drug treatment centres (2019), data on the prescriptions and supply of OSMs in prisons (2020), and data of sales of OSMs in France (2022).
The second part of the report presents data on misuse, deaths related to OSM drugs, and the sale of naloxone.